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Available online 13 June 2017Besides its essential role in the activation of HIV-1 gene expression, the viral Tat protein has the unusual property
of trafﬁcking in and out of cells. In contrast to Tat internalization, the mechanism involved in extracellular Tat re-
lease has so far remained elusive. Here we show that Tat secretion occurs through a Golgi-independent pathway
requiring binding of Tat with three short, non-consecutive intracytoplasmic loops at the C-terminus of the cellu-
lar Na+,K+-ATPase pump alpha subunit. Ouabain, a pump inhibitor, blocked this interaction and prevented Tat
secretion; virions produced in the presence of this drug were less infectious, consistent the capacity of virion-as-
sociated Tat to increase HIV-1 infectivity. Treatment of CD4+ T-cells with short peptides corresponding to the
Tat-binding regions of the pump alpha subunit impaired extracellular Tat release and blocked HIV-1 replication.
Thus, non canonical, extracellular Tat secretion is essential for viral infectivity.9 Trieste,
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The Tat protein of the human immunodeﬁciency virus type 1 (HIV-
1) is a small protein (101 aa in most clinical isolates, or 86 aa in the
widely utilized HXB2 laboratory strain), acting as a transcriptional acti-
vator of viral gene expression. At the viral long terminal repeat (LTR)
promoter, the protein binds a cis-acting RNA element (trans-activa-
tion-responsive region, TAR) present at the 5′-end of each viral tran-
script (Berkhout et al., 1989). Through this interaction, Tat activates
HIV-1 transcription by promoting the assembly of transcriptionally ac-
tive complexes at the LTR by multiple protein-protein interactions
(Giacca, 2004; Ott et al., 2011).Italy.
t'Anna, Pisa, Italy.
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n open access article underBesides regulating HIV-1 gene expression, N20 years ago it was ﬁrst
demonstrated that Tat also possesses the unusual property of entering
cells when present in the extracellular milieu (Frankel and Pabo,
1988; Green and Loewenstein, 1988). This propertywas later extensive-
ly characterized and shown to depend on a 9-aa long, arginine-rich se-
quence (aa 49–57), corresponding to the Tat basic domain, which also
mediates nuclear transport and TAR binding. Work performed in differ-
ent laboratories has shown that short peptides corresponding to this
amino acid stretch can be used as biotechnological tools for the intracel-
lular delivery of heterologous proteins, drugs, viral vectors, siRNAs and
nanoparticles (Fittipaldi and Giacca, 2005; Jones and Sayers, 2012;
Schmidt et al., 2010; Zhang and Wang, 2012).
We, and others have previously shown that extracellular Tat binds
heparin through its basic domain (Mann and Frankel, 1991; Rusnati et
al., 1997). We also showed that membrane bound-heparan sulfate pro-
teoglycans (HSPG) are the cell surface receptor for Tat internalization,
since cells that are genetically impaired in the synthesis of these mole-
cules fail to internalize the extracellular protein (Tyagi et al., 2001).
A few studies have also provided evidence in support of extracellular
Tat release from the expressing cells (Becker-Hapak et al., 2001; Chang
et al., 1997; Tasciotti and Giacca, 2005; Tyagi et al., 2001). The mecha-
nism underlying this process, however, has remained largely elusive.
The protein does not contain anN-terminal signal peptide driving its se-
cretion from the ER-Golgi pathway and, accordingly, protein export isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Chang et al., 1997). Thus, Tat is a member of the small group of hetero-
geneous proteins that exit the cells by a process termed “unconvention-
al” or “non-classical” protein secretion (Nickel and Rabouille, 2009).
Recent data show that recruitment of Tat to the inner leaﬂet of the plas-
ma membrane involves binding to membrane-associated phos-
phatidylinositol-4,5-bisphosphate (PI(4,5)P2) (Rayne et al., 2010),
with the consequent formation of membrane pores (Zeitler et al.,
2015); similar events occur for the unconventional secretion of FGF-2
(Temmerman et al., 2008). The mechanism for extracellular release of
Tat and the molecular identity of the secretory machinery involved,
however, remain elusive.
2. Materials and Methods
2.1. Plasmids, Peptides, Antibodies and Other Biological Reagents
Detailed description of the biological reagents used in this study is
presented in the Supplementary material.
2.2. Cell Cultures and Transfections
CHO K1 and psg A-745 (Rostand and Esko, 1997) were obtained
from the American Type Culture Collection (ATCC; Manassas, VA) and
maintained in Kaighn's modiﬁcation of Ham's F12 medium. HEK293T,
HeLa and U2OS (obtained from the ATCC) and HL3T1 cells (a HeLa
cells derivative stably transfected with a silent LTR-CAT cassette), a
kind gift of B. Felber, were maintained in DMEM. All culture media
were supplemented with 10% fetal calf serum, 2 mM L-glutamine, and
50 μg/ml gentamicin. U2OS cells (5 × 104) were seeded in four-well
glass chamber slides (LabTek II-Nalge Nunc) and transfected with the
Polyfect transfection kit (Qiagen) for 24 h. HEK293T cells were
transfected using standard calcium phosphate precipitation, incubated
for 36 h, and then processed for secretion or co-immunoprecipitation
experiments. Primary CD4+ T cells were isolated by negative selection
with a CD4+ T cell isolation kit (Miltenyi) from blood buffy coats from
healthy donors, according to an approved study protocol. Procedures for
lymphocyte isolation and culture were as described (Lusic et al., 2003;
Manganaro et al., 2010). All cell lines were routinely tested for Myco-
plasma contamination.
2.3. In Vitro Binding Assays
Binding of GST-fusedα1 fragments to 35S-Tat86 and 35S-Tat86(R5A)
was performed as follows. Brieﬂy, 1 μg of recombinant proteins, after
pretreatment in a solution containing DNase I 0.25 U/μl and RNase 0.2
μg/μl to remove contaminant bacterial nucleic acids, were incubated
with 600 c.p.m. of in vitro translated Tat in a solution containing
0.2 mg/ml ethidium bromide. Following extensive washes, the reaction
mixture was resolved by SDS–PAGE electrophoresis and analyzed by
phosphoimaging.
Synthetic biotinylated peptides, corresponding to P1, P2 and P3,
were used for binding assays as follows: 25 μl of streptavidin resin
(UltraLink Plus streptavidin beads, Pierce), were pretreated with 3 mg
of BSA for 10 min at room temperature, and subsequently incubated
with 50 μg of peptide at 22 °C for 1 h; after 3washes, the peptide-coated
beads were incubated with either 600 c.p.m. of in vitro translated Tat as
previously described, for 2 h at 4 °C. Following extensivewashes, the re-
actionmixturewas resolved by SDS–PAGE electrophoresis and analyzed
by phosphoimaging.
2.4. HIV-1 Tat Secretion Assay
HEK293T or CHO A-745 cells were seeded in 6-cm plates (1 × 106
cells/plate) one day prior to transfection; cells were transiently
transfected with either Tat11-TK, Tat86-TK or TK constructs and withthe Sc-VH16-SV5 construct as a positive control of classical secretion.
The calcium-phosphate-DNA complexes were incubated for 12 h, then
medium was replaced with fresh DMEM, and cells were incubated for
additional 24 h. The secretion assays were performed by washing the
cells (3washes of 10min each)withOptimem containing 20 μg/ml hep-
arin to prevent secreted Tat protein binding to the extracellular heparan
sulfate proteoglycans upon transfection (Tyagi et al., 2001), and incu-
bating the cells with 2 ml of Optimem plus heparin for the indicated
times. Following incubation, cell culture supernatants were collected
and concentrated using Amicon Ultra 10 concentrator (Millipore) ac-
cording to the manufacturer's instructions; the concentrated fraction
was then processed for western blotting. As a control of protein expres-
sion, the cellular fraction was collected, lysed in NHEN buffer (20 mM
Hepes pH 7.5, 300mMNaCl, 0.5%NP-40, 20% glycerol, 1mMEDTA) con-
taining protease inhibitors (Roche). Total protein concentration was
assessed by the Bradford assay (BioRad), and 30 μg of each sample
was processed for Western Blotting.
2.5. Transcellular Transactivation Assay
HEK293T cellswere transfectedwith a pcDNA3 construct expressing
Tat86 and a pcDNA3 expressing either wild typeα1 or one of the delet-
ed α1 mutants; after 24 h incubation, cells were washed and the medi-
um substituted with fresh medium plus heparin 20 μg/ml and, for the
secretion inhibition experiments, supplemented with 25 μM ouabain.
After 4 h, the supernatant was collected and added to HL3T1 cells, con-
taining an integrated bacterial chloramphenicol-acetyltransferase gene
(CAT) gene under the control of the HIV-1 LTR, in the presence of 100
μM chloroquine. After 24 h incubation, Tat-driven CAT expression was
assayed by quantifying the levels of CAT protein using a CAT ELISA kit
(Roche Diagnostics, Meylan, France).
2.6. Surface Plasmon Resonance (SPR) Binding Assay
SPR measurements were performed on a BIAcore X 100 instrument
(GE-healthcare). For the analysis of the direct binding of the Na+,K+-
ATPase alpha1 subunit peptides with Tat, Tat86 (40 μg/ml) was
immobilized to a CM5 sensorchip as described 65, leading to the immo-
bilization of 6990 resonance units (RU) equal to 0.6 pmol/mm2 of the
protein. A sensorchip activated and deactivated in the absence of any
protein was used as a negative control and for blank subtraction. In-
creasing concentrations of synthetic P1, P2, P3 peptides or of the fusion
protein GST-P1-P2-P3 in 10 mM HEPES buffer pH 7.4 containing
150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20 (HBS-EP+) were
injected over the Tat or control surfaces for 4 min and then washed
until dissociation was observed. The dissociation constant (Kd) of the
interactions were calculated by being ﬁtted with the proper form of
Scatchard's equation for the plot of the bound RU at equilibrium versus
the ligand concentration in solution. The software embedded in the
BIAcore X-100 instrument performed all ﬁttings.
For competition experiments, GST-P1-P2-P3 (20 μg/ml) was
immobilized to a CM4 sensorchip as described for Tat, allowing the im-
mobilization of 6100 RU equal to 0.6 pmol of the fusion protein. Similar
results were obtained for immobilization of gelatin, here used as a neg-
ative control and for blank subtraction. Synthetic Tat (300 nM) was
injected over the GST-P1P2P3 surface in the presence of increasing con-
centrations of the peptides under test. Injection lasted for 4min to allow
the association of Tat with the sensorchip-immobilized ligand. The re-
sponse (in RU) was recorded at the end of injection, and binding data
were plotted as percentage of maximal bound analyte in the various ex-
perimental conditions.
2.7. Virus Production and Infection
Infectious viral stocks were generated by transfecting the viral DNA
into HEK293T cells and collecting supernatants after 48 h. Viral
Fig. 1.Ouabain-sensitive secretion of Tat from the expressing cells. (a) Schematic representation of themajor functional domains ofHIV-1 Tat (acidic, cysteine-rich, core, andbasic). Tat has
101 aa in several clinical isolates and 86 aa in the laboratory strain HX2B. The amino acidic sequence of the basic domain of the protein, which imparts the protein intercellular trafﬁcking
capability, is indicated. The lower part of the panel shows a schematic representation of the two Tat proteins used in this study (Tat11, corresponding to the Tat basic domain plus two
additional amino acids at both extremities, and Tat86). (b) Tat86-TK and Tat11-TK are released from the expressing cells and bind extracellular HSPG upon secretion. The
immunoblots in the upper panel show the amount of proteins released in the cell culture supernatants of cells transfected with Tat86-TK, Tat11-TK or scVH16-SV5, treated or
untreated with 25 μM soluble heparin. The immunoblots in the lower part show the levels of intracellular protein expression in the same samples. WCL: whole cell lysates. The
asterisk (*) indicates an additional band present in the Tat86-TK immunoblots, probably corresponding to a degradation product. Lack of tubulin immunoreactivity in the supernatants
indicates the absence of appreciable cell lysis. (c) Sensitivity of Tat11-TK and scFv secretion to the indicated drugs. HEK293T cells were co-transfected with Tat and scFV expressing
plasmids and treated with the indicated metabolic drugs. The amount of secreted protein was assessed by western blot on cell culture supernatants, while protein expression and
loading was checked on whole cell lysates (WCL). BFA: brefeldin A (10 μM); OUA: ouabain (25 μM); CURC: curcumin (50 μM); METH: methylamine (1 mM); EIPA: 5-(N-ethyl-N-
isopropyl)amiloride (20 μM); GLY: glyburide (10 μM). (d) Sensitivity of Tat86-TK and scFv secretion to the indicated drugs. HEK293T cells were co-transfected with Tat and scFV
expressing plasmids and treated with the indicated metabolic drugs. The amount of secreted protein was assessed by western blot on cell culture supernatants, while protein
expression and loading was checked on whole cell lysates (WCL). BFA: brefeldin A; OUA: ouabain; CURC: curcumin; METH: methylamine; EIPA: 5-(N-ethyl-N-isopropyl)amiloride;
GLY: glyburide. (e) Quantiﬁcation of Tat11-TK and ScVH16 secretion in ouabain-treated cells. The amount of extracellular proteins, normalized over the levels of intracellular
expression, was assessed after a 4 h incubation. Data are mean ± sem of three independent experiments. **P-value b 0.01. (f) Quantiﬁcation of Tat86-TK and ScVH16 secretion in
ouabain-treated cells. The amount of extracellular proteins, normalized over the levels of intracellular expression, was assessed after a 4 h incubation. Data are mean ± sem of three
independent experiments. **P-value b 0.01. (g) Tat co-immunoprecipitates with the endogenous Na+,K+-ATPase α1 subunit; binding is sensitive to ouabain. HEK293T cells were
transfected with Tat86-TK or TK as a control and treated with ouabain (25 μM) as indicated. The antibodies used for immunoprecipitation and subsequent western blots are indicated
on the right side. Expression of endogenous α1 and either of the transfected proteins was veriﬁed in whole cell lysates (WCL). The bands marked with (*) are degradation products.
(h) Downregulation of cellular Na+,K+-ATPase α1 subunit impairs Tat release. The amount of released Tat was monitored in cell culture supernatants of Na+,K+-ATPase α1-knock
down cells by immuno blotting with an anti-Tat antibody; protein expression and loading were checked in whole cell lysates (WCL). (i) Quantiﬁcation of the levels of Tat secretion
after α1 RNAi knock down. Data are mean ± sem of three independent experiments.
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content using the Innotest HIV antigen mAB kit (Innogenetics N.V.
Gent, Belgium). Before infection, the viral stock was treated with
40 U/ml DNAse I (Life Sciences) for 1 h at 25 °C. Activated T cells (1
× 106) were then infected with 500 ng/ml of p24 for 4–5 h at 37 °C. In-
fection was carried out for 4 h in the presence of polybrene (Sigma).
After infection, the cells were kept in culture at 1 × 106 cells/ml in com-
plete medium supplemented with IL-2. At days 3, 5, 7, 10 and 14 post-
infection, media and IL-2 were replaced and cells were kept at a density
of 1 × 106/ml. The Env- molecular clone pNL4–3/Luc E−R−, a kind gift
from Nathaniel Landau, harbors a frameshift mutation introduced near
the 5′ end of env gene (Connor et al., 1995), and performs a single-
round infection once pseudotyped with the Vesicular Stomatitis
Virus–G (VSV-G) protein. Integrated viral DNA was quantiﬁed by the
Alu-PCR technique using a described procedure (Manganaro et al.,
2010).
2.8. Other Methods
Other, more standardmethods are reported in the Supplemental Ex-
perimental Procedures.
3. Results
3.1. The Cardiac Glycoside Ouabain Blocks Extracellular Release of HIV-1 Tat
We developed an assay in which HEK293T cells are simultaneously
transfected with a plasmid expressing a single-chain Fv antibody (scFv)
tagged with the SV-5 epitope (ScVH16-SV5), containing and N-terminal
signal peptide for ER-Golgi secretion, together with another plasmid cod-
ing for either the HIV-1HX2B 86 aa Tat (Tat86) or the Tat fragment corre-
sponding to aa 48–59 (Tat11), encompassing the 9-aa-long, basic region
of Tat (Fig. 1a); the HSV1 thymidine kinase protein (TK) served as a re-
porter (Tasciotti and Giacca, 2005; Tasciotti et al., 2003). At 36 h after
transfection, ~2–10% of both Tat86-TK and Tat11-TK was found in the
cell culture supernatants alongwith the scFv and in the absence of detect-
able cell lysis (Fig. 1b). The amount of free Tat-TK protein in the superna-
tant was increased by cell treatment with heparin, which released
membrane-attached, extracellular Tat (Fig. 1c). Tat86 release depended
on the integrity of the protein basic domain, since the transactivation-
dead mutant Tat86(R5A), bearing alanine to arginine substitutions in
the Tat basic domain (Demarchi et al., 1999), failed to be exported from
the cells (Figs. S1a and S1b). Fusion proteins between Tat11 and EGFP
or Cre were released similar to Tat11-TK (not shown).
The mechanism involved in extracellular Tat release was investigated
by testing a panel ofmetabolic drugs. No effect was detected on either Tat
release or scFv secretion by glyburide (GLY) and methylamine (METH),
which block the non-classical secretion of other proteins (Hamon et al.,
1997; Rubartelli et al., 1990) or 5-(N-ethyl-N-isopropyl)amiloride
(EIPA), a drug interfering with macropinocytosis (West et al., 1989) and
known to limit HIV-1 replication (Ewart et al., 2004). Brefeldin A (BFA),
which inhibits the ER-Golgi trafﬁcking (Misumi et al., 1986), impaired
scFv antibody secretion but not Tat release, while the cardiac glycoside
ouabain (OUA), which abrogates the function of the cell membrane
Na+,K+-ATPase, selectively abolished Tat-fusion protein release (Fig. 1c
and d for Tat11-TK and Tat86-TK respectively). Of interest, curcumine
(CURC), a broad inhibitor of P-type ATPases, was instead ineffective, sug-
gesting that the effect of ouabain was not related to the inhibition of the
enzymatic function of the ATPase. Ouabain did not affect Tat protein pro-
duction, since the levels of the protein in whole cell extracts were un-
changed in the drug-treated cells. Quantiﬁcation of the inhibitory effect
of ouabain on secretion the two Tat fusion proteins is shown in Fig. 1e
and f; a series of Tat exit experiments using higher concentration of the
other drugs conﬁrmed the speciﬁcity of ouabain (Fig. S1c and d). There
was no apparent toxicity of OUA when used at a concentration of up to
25 μM in different cell lines (Fig. S1f–i).3.2. Ouabain-sensitive Binding of HIV Tat to the Cellular Na+,K+-ATPaseα1
Subunit
The speciﬁc cellular target of ouabain is the α subunit of the mem-
brane Na+,K+-ATPase pump, which catalyzes ATP hydrolysis coupled
with Na+ and K+ transfer through the membrane against the electro-
chemical gradient (Kaplan, 2002; Lingrel and Kuntzweiler, 1994). In
cells transfected with Tat86, we indeed found that the endogenous
Na+,K+-ATPaseα1 subunit co-immunoprecipitatedwith Tat; cell treat-
ment with ouabain for 4 h abolished this interaction (Fig. 1g); instead,
the β1-subunit was not present in the anti-Tat immunoprecipitate
(Fig. S1e). Noticeably, transient inhibition of Na+,K+-ATPaseα1 expres-
sion by RNAi completely inhibited Tat release (Fig. 1h and i).
The rat Na+,K+-ATPase enzyme is insensitive to ouabain (Emanuel
et al., 1988) because its α1 subunit harbors two point mutations at
Gln111 and Asn122 that reduce afﬁnity to the drug (Laursen et al.,
2013; Price and Lingrel, 1988); Fig. 2a. This rat Na+,K+-ATPaseα1 pro-
tein was still capable to bind both Tat11- and Tat86-TK in co-IP experi-
ments (Fig. 2b); the same was also true for the rat α1 single point
mutant D716N, in which catalytic activity is impaired (Lane et al.,
1993); Fig. 2c. The latter result is consistent with the conclusion that
the interaction between Tat and α1 occurs independent from the
Na+,K+-ATPase enzymatic activity. Of notice, overexpression of both
wt andD716N ratα1 proteins rescued the suppressive effect of ouabain
on Tat secretion in human cells (shown in Fig. 2d and e for Tat86 and
Tat11 respectively). Secretion of ScVH16-SV5 was unaffected by any of
these treatments.
Collectively, these results indicate that proteins containing the 11-aa
long, Tat basic domain are effectively released by the expressing cells
through a non canonical secretion mechanism that involves binding of
Tat to the Na+,K+-ATPase α1 subunit but does not require the pump
enzymatic activity.
3.3. The C-terminus of Na+,K+-ATPase α1 is Essential to Bind Tat and Me-
diate Its Secretion
A rat Na+,K+-ATPase α1 deletion mutant lacking the C-terminal re-
gion (rΑlpha1ΔC, carrying a deletion from aa 784 to the C-terminus of
the protein; Fig. 2a) neither bound Tat (Fig. 2f) nor permitted extracellu-
lar Tat release in human cells treated with ouabain, in contrast to either
wt rat α1 and the rΑlpha1(D716N) mutant (Fig. 2e); the secretion of
the scFv antibody was unaffected by any of these conditions. All three
rat proteinswere expressed at comparable levels inside the cells (Fig. S2).
The essential role of the α1 subunit C-terminus in Tat binding and
secretion was also strengthened by the results of a transcellular
transactivation assay, in which the supernatants of HEK293T cells,
transfected with wild type Tat86 and wild type rΑlpha1 or mutants
rΑlpha1(D716N) and rΑlpha1ΔC, with or without ouabain, were sub-
sequently incubated for 24 h with reporter HL3T1 cells, carrying the
HIV-1 LTR upstream of the CAT reporter gene. Ouabain blocked trans-
cellular transactivation mediated by the supernatant of Tat86-
transfected cells. The effect of the drug was overcome by transfection
of either wild type rat rΑlpha1 or rΑlpha1(D716N), but not by
rΑlpha1ΔC (Fig. 2g).
Collectively, these results indicate that Tat binds the C-terminal cyto-
plasmic region of the Na+,K+-ATPaseα1 subunit inside the cells and that
integrity of this region is an essential requisite for extracellular Tat export.
3.4. The Tat Basic Domain Binds the Na+,K+-ATPaseα1 Subunit C-terminal
Domain Cytoplasmic Loops
Next we wanted to deﬁne the regions of Tat and Na+,K+-ATPaseα1
involved in the interaction. Theα1 subunit is a large, integralmembrane
proteinwith 10 transmembrane-spanning domains plus cytoplasmic N-
and C-terminal regions (Morth et al., 2007) (Fig. 3a). In GST-pulldown
assays, radiolabeled Tat did not bind any of the three large, N-
174 S. Agostini et al. / EBioMedicine 21 (2017) 170–181terminal cytoplasmic segments of ratα1; in contrast, it showed binding
to a fusion protein corresponding to the threeα1 C-terminal short cyto-
plasmic peptides, hereafter named P1-P2-P3 (residues 824–843, 939–
951 and 1007–1023, respectively; Fig. 3b and c). Co-IP experiments be-
tween Tat86-TK and Flag-P1-P2-P3 fusion protein conﬁrmed this inter-
action in the cells (Fig. 3d). The Tat86(R5A) mutant failed to interact
with any of the analyzed α1 regions (Fig. S3a). Binding to radiolabeled
Tat was detected using all three P1, P2 and P3- mostly with P2-, obtain-
ed as independent, biotinylated peptides (Fig. 3e); again, the
Tat86(R5A) mutant scored negative in this assay (Fig. S3b).
Next we analyzed binding of the α1 P1-P2-P3 fusion protein to
sensor chip-immobilized Tat by surface plasmon resonance (SPR).
We found that binding occurred with a Kd value of 1.6 μM, which
was saturable. Neither control GST alone bound immobilized Tat
(Fig. 3f) nor P1-P2-P3 bound to a negative control surface (not
shown). When tested individually, the P1, P2 and P3 peptides also
bound immobilized Tat in a dose-dependentmanner, however at con-
centrations ranging from 250 to 2000 μM (Fig. 3f). Binding of these
peptides was speciﬁc, since a scrambled P3 peptide was ineffective
when assayed up to 2 mM. None of the three peptides bound the con-
trol surface (data not shown).
We further investigated the capacity of an equimolar mixture of the
individual P1, P2 and P3 peptides (hereafter named PMIX) to compete
for the α1-Tat interaction by SPR. We found that PMIX effectively
averted binding of Tat to immobilized GST-P1-P2-P3, with an ID50
equal to 0.5 μM (Fig. 3g). When the three peptides were tested individ-
ually, only P2 was effective at signiﬁcantly higher concentrations (ID50
= 10 μM).
The amino acid sequences of theα1 P1, P2 and P3 loops of are highly
conserved in rat, human and pig (Fig. S3c). Analysis of their spatial ar-
rangement indicates that are very close to one another in the 3D struc-
ture of the α1 protein (Morth et al., 2007; Yatime et al., 2011), thus
possibly forming an integrated docking surface for Tat protein binding
(Fig. 3h). Perturbation of this structure induced by ouabain binding in
a cavity of the transmembrane spans of the protein (Morth et al.,
2007; Yatime et al., 2011) might explain the inhibitory effect exerted
by the drug on the Tat- α1 interaction and Tat secretion.
3.5. Cellular Na+,K+-ATPase α1 Subunit is Essential for Productive HIV-1
Infection
Wewanted to understand the relevance of Na+,K+-ATPase–mediat-
ed Tat secretion in the context of HIV-1 infection. First, we tested effect
of ouabain on virion production.We found that the drug, once added to
HEK293T cells transfected with the pNL4.3.Luc.R-E HIV-1 molecular
clone (Fig. 4a), signiﬁcantly decreased the production of VSV-G
pseudotyped virions (Fig. 4b). The same was also observed for wt HIV-
1BRU virions (Figs. S4a and S4b).
More remarkably, virions produced in the presence of the drugwere
markedly less infectious than those produced in untreated cells. ThisFig. 2. In vivo characterization of the interaction of Tat with the Na+,K+-ATPase α1. (a) Sche
association with Tat inside the cells. (b) Tat co-immunoprecipitates with transfected rat α1 p
(rAlpha1), Tat86-TK, Tat11-TK and TK control and treated with ouabain as indicated. The anti
right side. Expression of the transfected proteins was veriﬁed in whole cell lysates (WCL). The
transfected rat α1 wild type and catalytically inactive rat α1 D716N mutant; binding is not se
tagged, mutant rat α1 (rAlpha D716N) instead of wt α1. (d) Both wt rat α1 and the D716N c
HEK 293T cells were transfected with Tat86-TK, ScVH16 as a secretion control, and either w
indicated. The amount of secreted protein was assessed by immunoblot on cell culture super
rAlphaΔC fails to rescue Tat secretion in human cells treated with ouabain. Cells were transfec
catalytically inactive α1 (rAlpha1(D716N)) or the truncated mutant rAlphaΔC, and treated
immunoblot on cell culture supernatants; total protein expression was veriﬁed in whole
immunoprecipitate Tat. Human HEK 293T cells were transfected with Tat11-TK and ei
immunoprecipitation and subsequent western blots are indicated on the right side. (g) Resul
catalytically-inactive mutant, but not the rAlphaΔC C-terminus-truncated mutant, rescues sec
were transfected with an expression vector for Tat86 alone, or cotransfected with wt rat α1 (r
(25 μM), as indicated, and their supernatants were then incubated with HL3T1 cells, carrying
activation were assessed by measuring CAT levels by an ELISA assay. sn: supernatant. **: P b 0.conclusion was reached by testing the effect of the same number of
VSVG-pseudotyped virions (2 μg p24 per 1 × 106 cells), produced in
the presence or absence of ouabain, on Jurkat cells (Fig. 4c and d) as
well of wt HIV-1BRU on both Jurkat cells (Fig. 4f and g) and primary
CD4+ lymphocytes (Fig. 4i). For both VSV-G and wt viruses, decreased
infectivity correlatedwith reduced viral integration in the target cells, as
assessed by Alu-LTR measurements (Fig. 4e and h respectively). Oua-
bain did not exert signiﬁcant cell toxicity when administered to cells
during the 15 h-long virus production period (Fig. S4c). The effect of
ouabain appeared to speciﬁcally affect infectivity of virions at the level
of virus production and not infection per se, since HIV-1 virions pro-
duced without ouabain, when used to infect Jurkat cells, were unaffect-
ed by the presence of the drug (Fig. S4d and Ee).
Next, we tested whether the downregulation of cellular Na+,K+-
ATPase α1 by RNAi mimicked the inhibitory effect of ouabain on viral
production (Fig. 4j). Treatment of HEK293T cells with an anti- α1
siRNA pool markedly impaired HIV-1 production; two control, non-
targeting siRNAs (siNT1 and siNT3) had no apparent effect (Fig. 4k
and l). Finally, we observed that, on the contrary, transfection of an ex-
pression vector for rAlpha1, but not for the C-terminal mutant
rAlpha1ΔC, determined a N3-fold increase in HIV-1 p24 protein in the
supernatants (Fig. 4m and n); both wt and mutant proteins were
overexpressed at comparable levels (Fig. 4o).
3.6. Exogenous Tat Reconstitutes Infectivity of HIV-1 Virions Produced in the
Presence of Ouabain
Previouswork had indicated that secreted Tat is foundon the surface
of HIV-1 virions and takes part in virion infectivity by enhancing surface
attachment and entry into the target cells (Gratton et al., 2003; Marchiò
et al., 2005). We therefore tested whether exogenous addition of Tat-
containing supernatants to virions produced in the presence of ouabain
could rescue infectivity; the same supernatants, depleted of Tat using an
anti-Tat speciﬁc antibody, served as a control (Fig. 5a and b). We found
that the Tat-containing supernatants, but not those after Tat
immunodepletion, rescued infectivity of the virions in a dose-depen-
dent manner, as measured by both luciferase activity and levels of inte-
gratedHIV-1DNA in the target cells (Fig. 5c andd respectively). The Tat-
containing supernatant exerted no toxic effects on Jurkat or CHO cells
(Fig. S5a and b). Rescue of infectivity was also obtained using a recom-
binant GST-Tat protein (Fig. S5c and d). Of interest, in both cases supple-
mentation with scalar doses generated a bell-shaped infectivity curve,
being less effective at higher concentrations. In addition to VSV-G-
pseudotyped virions exogenous addition of Tat also enhanced infectivi-
ty of wt HIV-1 produced in the presence of ouabain, again with a bell-
shaped response (Fig. 5e).
Finally, we previously observed that the main cell surface receptors
for extracellular Tat are the cell membrane-bound heparan-sulfate pro-
teoglycans and that cells lacking these molecules fail to bind and inter-
nalize the protein (Fittipaldi et al., 2003). We therefore wanted to testmatic representation of the rat Na+,K+-ATPase α1 subunit constructs used to determine
rotein; binding is not sensitive to ouabain. HEK 293T cells were transfected with rat α1
bodies used for immunoprecipitation and subsequent western blots are indicated on the
band marked with (*) is a degradation product. (c) Tat co-immunoprecipitates with the
nsitive to ouabain. The experiment was performed as in panel (b) by transfecting FLAG-
atalytically inactive mutant rescue Tat86 secretion in human cells treated with ouabain.
t rat α1or FLAG-tagged, mutant rat α1 (rAlpha D716N), and treated with ouabain as
natants, while intracellular protein expression was assessed on whole lysates (WCL). (e)
ted with Tat11-TK and the scFv antibody ScVH16-V5, together with wt rat α1 (rAlpha1),
with ouabain (25 μM) as indicated. The amount of secreted protein was assessed by
cell lysates (WCL). (f) The rat α1 C-terminal deletion mutant rAlphaΔC fails to co-
ther the wt rat α1or the α1C-terminus truncated mutant. The antibodies used for
ts of transcellular transactivation assay showing that the rat Na+,K+-ATPase α1(D716N)
retion of transcriptionally active Tat in human cells treated with ouabain. HEK293T cells
Alpha1), mutant rAlpha D716N or mutant rAlphaΔC; the cells were treated with ouabain
an LTR-CAT reporter cassette to measure transcellular transactivation. The levels of LTR
01 over Tat86.
175S. Agostini et al. / EBioMedicine 21 (2017) 170–181the effect of pseudotyped virion-associated Tat on the infection of the
CHO A-745 cell mutant, which is impaired in glycosaminoglycan
biosynthesis (Esko et al., 1985). We found that, in contrast to wt
CHO K1 cells, infectivity of pseudotyped virions produced in the
presence of ouabain was not rescued by exogenous Tat addition
(Fig. 5f).
Taken together, these observations are consistent with the conclu-
sion that a major function of virion-bound Tat is to modify the interac-
tion of the virus particle with the cells to be infected, with the
ultimate effect of increasing infectivity.3.7. Peptides Corresponding to the α1 C-terminal Loops Inhibit Tat release
and HIV-1 Infection
Our protein binding data indicated that the P1, P2 and P3 peptides,
corresponding to the C-terminal α1 intracytoplasmic loops, bound Tat.
We therefore tested whether these peptides, by competing for endoge-
nous α1 binding, might also affect extracellular Tat release and HIV-1
replication. Initially, we observed that all three peptides, once conjugat-
ed to ﬂuorescein, were internalized in a dose-dependentmanner, as de-
tected by ﬂow cytometry at 4 h after addition to the cells, following
Fig. 3. Tat binds rat Na+,K+-ATPase α1 in vitro – Mapping of the interacting regions. (a) Scheme of the Na+,K+-ATPase α1 subunit structure and membrane topology; the cytoplasmic
domains are indicated. (b) Schematic representation of the rat α1 fragments used for the pull-down assay shown in panel c. (c) Tat protein binds the C-terminal cytoplasmic region of
the rat α1 subunit in vitro. The indicated fragments of the rat α1 protein fused to GST or GST alone were incubated with invitro translated [35S]-Tat86, extensively washed, and then
resolved by SDS-PAGE. Each panel shows the gel exposed to a phosphoimager from a representative experiment along with the quantiﬁcation of the amount of bound proteins
expressed as a percentage of radiolabeled input. These and all the subsequent pulldown experiments were performed at least in triplicate with superimposable results. (d) Co-
immunoprecipitation of Tat with the P1-P2-P3 fusion protein, corresponding to the small cytosolic loops of the Na+,K+-ATPase α1 subunit. The antibodies used for
immunoprecipitation and subsequent western blots are indicated on the right side. Expression of the transfected proteins was veriﬁed in whole cell lysates (WCL). (e) Tat individually
binds three cytoplasmic peptides corresponding to the C-terminal loop of the Na+,K+-ATPase α1 subunit. Biotinylated peptides were bound to streptavidin beads, incubated with
[35S]-Tat86, extensively washed, and then resolved by SDS-PAGE. (f) Surface Plasmon resonance (SPR) analysis of Na+,K+-ATPase α1 peptides -Tat interaction. The curves were
obtained using the blank subtracted values of resonance unit (RU) bound at equilibrium after injection onto sensorchip-immobilized Tat of increasing concentrations of the indicated
Na+,K+-ATPase α1 peptides (P1, P2 and P3) or of a GST-protein containing the fusion of their three sequences (GST-P1-P2-P3). The P1, P2 and P3 peptides bound Tat in a dose-
dependent manner, while a scrambled P3 control peptide was ineffective. The fusion protein bound Tat more effectively than the individual synthetic peptides. (g) Peptides from the
Na+,K+-ATPase α1 C-terminal domain competitively affect the binding of Tat to the fusion P1-P2-P3 protein in SPR analysis. Increasing concentrations of synthetic P1, P2 or P3
peptides or of a mix of the three peptides (PMIX) were evaluated for their capacity to prevent binding of Tat to sensorchip-immobilized GST-P1P2P3 fusion protein. The responses are
plotted as percentages of Tat binding in the absence of free antagonist. (h) 3D modeling of the Na+,K+-ATPase α1 structure, as resolved by X-ray crystallography (Yatime et al., 2011).
The PDB ﬁle (PDB ID: 3N23 and 3N2F) was visualized by PyMoL tool, available at www.pymol.org; the regions corresponding to the three C-terminal cytoplasmic peptides are
highlighted. The inset shows the 3D organization of the three C-terminal cytoplasmic peptides of the Na+,K+-ATPase α1subunit in the absence of ouabain.
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Fig. 4. Na+,K+-ATPase Inhibition by ouabain orα1 downregulation by RNAi inhibit HIV-1 production and virion infectivity. (a) Scheme of the experiment to assess viral production from
the VSV-G-pseudotyped HIV-1NL4.3E-R-Luc in the presence of ouabain. (b) Ouabain impairs viral production. Levels of p24, measured by ELISA, produced by HEK293T cells transfectedwith
theHIV-1NL4.3E-R-Lucmolecular clone and a VSV-G-expressing plasmid in the presence of ouabain (1 μM). **: P b 0.01 over untreated cells. (c) Scheme of the experiment to assess infectivity
of HIV-1 virions produced in the presence of ouabain. (d and e) HIV-1 produced in the presence of ouabain is less infectious. Jurkat cells were infected with the same amount of VSV-G-
pseudotyped HIV-1NL4.3E-R-Luc produced in the presence or absence of ouabain (1 μM); infection wasmonitored after 72 h bymeasuring luciferase activity (d) and the levels of integrated
viral DNA by Alu-PCR (e) in the infected cells. **: P b 0.01 over cells infectedwith a virus producedwithout ouabain. (f) Scheme of the experiment to assess infectivity of HIV-1BRU virions
produced in the presence of ouabain. (g–i) HIV-1BRU produced in the presence of ouabain is less infectious. Jurkat cells (panels g and h) or primary CD4+ T cells (panel g) were infected
with the same amount of HIV-1BRU produced either in the presence or absence of ouabain at the indicated concentrations; infection was monitored after 72 h by measuring p24 levels (g
and i) and the amount of integrated viral DNA by Alu-PCR (h) in the infected cells. **: P b 0.01 over cells infected with a virus produced without ouabain. (j) Scheme of the experiment to
assess the effect of transient depletion of cellular Na+,K+-ATPase α1 on HIV-1 production. Na+,K+-ATPase α1-depleted and control cells were transfected with the wild type HIV-1NL4.3
molecular clone and, after 48 h, viral production was monitored by p24 ELISA in cell culture supernatant. (k) Western blot showing silencing of Na+,K+-ATPase α1 in siRNA-transfected
cells. siNT1 and siNT3 are twonon-targeting siRNA controls. (l) Downregulation of cellular Na+,K+-ATPaseα1 impairs HIV-1 production.Na+,K+-ATPaseα1-knockdownand control cells
were transfectedwith theHIV-1NL4.3molecular clone and, after 48 h, virus productionwasmonitored byp24 ELISA in the cell culture supernatants. (m) Schemeof the experiment to assess
the effect of full length and mutant rat α1 overexpression on HIV-1 production. (n) Western blotting showing overexpression of full length and rAlphaΔC in HEK293T cell, visualized by
both anti-FLAG and anti- α1 antibodies. (o) Overexpression of wild type rat α1, but not of its truncated mutant rAlphaΔC, increases HIV-1 production. The levels of p24 present in the
supernatants of HEK293T cells transfectedwith either of the two constructs and laterwith theHIV-1NL4.3molecular clonewere assessed by ELISA.Data aremean±sd of three experiments.
177S. Agostini et al. / EBioMedicine 21 (2017) 170–181extensive cell trypsinization and washings to remove extracellular ma-
terial (Fig. 6a and Figs. S6a and S6b for the equimolar mixture of the
three peptides, PMIX, and the individual peptides, respectively). Indeed,
when cells transfected with Tat and the ScVH16-SV5 antibody were
treated with the individual peptides or with PMIX, extracellular Tat re-
lease was inhibited, leaving secretion of the scFv antibody unaffected
(Fig. 6b and S6c).
Next, a single-round infection experiment was performed by using
VSV-G-pseudotyped HIV-1NL4.3E-R-Luc to infect Jurkat cells that were
pre-incubated with different concentrations of PMIX or a control pep-
tide (Fig. 6c). At 72 h after infection, A dose-dependent decrease in lucif-
erase activity was clearly detected (Fig. 6d). This was paralleled by
decreased levels of integrated viral DNA (Fig. S6e).
We also analyzed the effect of PMIX on the infection of Jurkat cells
withwild typeHIV-1BRU virus. Over the course of 15 days after infection,
half of the cellmediumwas replaced every third daywith freshmedium
containing either PMIX or a control peptide (Fig. 6f). PMIX markedly
suppressed viral infection (Fig. 6g). Finally, PMIX also suppressed HIV-
1BRU integration at 72 h after infection (Fig. 6h). Analogous resultswere also obtained by testing the effects of PMIX on HIV-1BRU infection
of primary CD4+T cells (Fig. S6d and e). No apparent cellular toxicity of
PMIX was detected (Fig. S6f).
Collectively, these results indicate that suppression of extracellular
Tat release by peptides derived from the Na+,K+-ATPase α1 subunit
C-terminal domain impair HIV-1 infection.
4. Discussion
Our experiments indicate that theα subunit of the cellular Na+,K+-
ATPase mediates unconventional Tat secretion in a ouabain-sensitive
manner. Extracellular Tat release was affected neither by methylamine
(a drug which blocks endosomal recycling and impairs IL1B and FGF-2
non canonical secretion, implying a vesicular intermediate in their re-
lease (Hamon et al., 1997; Rubartelli et al., 1990; Zhou et al., 2002)),
nor glyburide (a sulfonylurea interferingwith the ABC-1 transporter es-
sential for the secretion of Galectin-1 (Flieger et al., 2003; Hamon et al.,
1997)). In contrast, Tat secretion was markedly sensitive to ouabain, an
inhibitor of the Na+,K+-ATPase. The observations that Tat secretion still
Fig. 5. Exogenously added Tat rescues infectivity of HIV-1 virions produced by ouabain-treated cells. (a) Scheme of the procedure to assess reconstitution of the infectivity of virus
produced in the presence of ouabain by exogenously added Tat protein-containing supernatant. VSV-G pseudotyped HIV-1NL4.3E-R-luc was produced in the presence of ouabain 1 μM; at
the time of infection of HeLa cells, virions were incubated scalar amounts of Tat-containing supernatant. (b) Western blot analysis of the cell culture supernatants containing Tat
before (control) and after immunodepletion with an anti-Tat monoclonal antibody (for 30 min at 37 °C). (c and d) Rescue of infectivity of virions produced in the presence of ouabain
by supernatants containing Tat. VSV-G pseudotyped HIV-1NL4.3E-R-luc produced in the presence of ouabain 1 μM; at the time of infection of HeLa cells, virions were incubated with the
indicated amounts of the Tat-containing supernatant or the same after immunodepletion using an anti-Tat monoclonal antibody. The levels of luciferase measured in the infected cells
at 48 h after infection are shown in panel C while the amount of integrated viral DNA in panel D. Data are mean ± sd of three experiments; **: P b 0.01 (e) Rescue of infectivity of wild
type HIV-1NL4.3 virions produced in the presence of ouabain by supernatants containing Tat. Infection was performed in Jurkat cells; the graphs shows the levels of p24 produced. Data
are mean ± sd of three experiments; **: P b 0.01. (f) Exogenous Tat fails to rescue infectivity of VSV-G pseudotyped HIV-1NL4.3E-R-luc produced in the presence of ouabain in the CHO
psg A-745 cell clone, which is defective in proteoglycan synthesis. Rescue experiments were performed as above in wt CHO K1 cells and the mutant. Data are mean ± sd of three
experiments; **: P b 0.01.
178 S. Agostini et al. / EBioMedicine 21 (2017) 170–181occurred in the presence of curcumin, an inhibitor of all P-type ATPases
(including the Na+,K+-ATPase) and that the rat D716N α1 mutant,
which is impaired in catalytic function (Lane et al., 1993), still rescued
Tat secretion in human cells treated with ouabain, are concordant in in-
dicating that the effect of the Na+,K+-ATPase on extracellular Tat re-
lease is independent from its enzymatic activity while still demands
physical binding of α1 to Tat.
These characteristics of Tat secretion are remarkably overlapping
with those of cellular FGF-2, which is also sensitive to ouabain and in-
volves binding of the factor to the Na+,K+-ATPase (Dahl et al., 2000;
Florkiewicz et al., 1998; Smith et al., 2001; Trudel et al., 2000; Zeitler
et al., 2015), while does not require integrity of the enzymatic functionof thepump (Zacherl et al., 2015).Work fromother laboratories has also
shown that unconventional secretion of both FGF-2 (Temmerman et al.,
2008) and HIV-1 Tat (Rayne et al., 2010) require interaction of the two
proteins with acidic domains in the phospholipid components of the
inner membrane leaﬂet. Thus, the Na+,K+ ATPaseα subunit might rep-
resent a preferential landing site for the association of Tat to the inner
membrane leaﬂet, which cooperates with PI(4,5)P2 in docking Tat to
the plasma membrane to favor its extracellular export, similar to what
proposed for FGF-2 (Zacherl et al., 2015).
The ouabain binding site is a cavity in the transmembrane domain at
the extracellular interface of the protein (Morth et al., 2007; Yatime et
al., 2011). It can be speculated that this interaction determines some
Fig. 6. Synthetic peptides corresponding to the Na+,K+-ATPase α1 C-terminal loops inhibit Tat secretion and HIV-1 infection (a) Peptides mixture (PMIX) of intracellular loops of the
Na+,K+-ATPase α1 subunit C-terminal domain are internalized by the cells. Different amounts of an equimolar mixture of ﬂuorescein-tagged peptides (PMIX) were added, at the
indicated concentrations, to HEK293T cells cultured in OPTIMEM medium. After 4 h, cells were tryspinized, extensively washed, and analyzed by ﬂow cytometry. The overlay plots
show the cell mean ﬂuorescence for increasing concentrations of the peptide mix. (b) Cell treatment with PMIX peptides blocks Tat86-TK release. Cells were transfected with Tat86-TK
and the ScVH16 scFv antibody and, after 36 h, washed with heparin and then treated with equimolar amounts of the three peptides (PMIX); presence of Tat86-TK and the scFv
antibody in the cell culture supernatant was analyzed by western blotting after a 4 h incubation. The levels of intracellular protein expression were veriﬁed on whole cell lysates
(WCL). (c) Scheme of the procedure to assess the effect of PMIX in a single-round HIV-1 infection. (d) Treatment with the PMIX peptides impairs HIV-1 infection in a single-round cell
infection assay. Jurkat cells were infected with HIV-1NL4.3E-R-Luc pseudotyped with the VSV-G envelope. Before infection, cells were incubated with different concentrations of the PMIX
peptides at 37 °C for 1 h. Then, cells were infected with the virus for 4 h, washed and fresh medium with peptides was added; after additional 72 h, cells were harvested and luciferase
expression level was measured. *: P b 0.05 and **: P b 0.01 over untreated cells, respectively. (e) Quantiﬁcation of viral integration after infection in the presence of PMIX. DNA from
Jurkat cells infected as in panel (d) was analyzed for the levels of proviral integration by Alu-PCR. *: P b 0.05 and **: P b 0.01 over untreated cells, respectively. (f) Scheme of the
experiment to assess the effect of PMIX on multiple rounds of infection by wild type HIV-1. (g) The PMIX peptides inhibit HIV-1 replication. Jurkat cells were infected with wild type
HIV-1BRU virus for 4 h in the presence of the PMIX peptides or of a control peptide (both at 5 μM). After infection, the medium containing the virus was washed and substituted with
fresh medium, containing the corresponding peptide preparation. At time = 0 and, subsequently, every 3 days until the 15th day, the supernatants were tested for reverse
transcriptase (RT) activity, while the infected cells were diluted 1:2 and fresh peptides were added to the culture media. (h) Quantiﬁcation of viral DNA integration after inhibition of
viral replication by PMIX. DNA from Jurkat cells treated as in panel (g) was analyzed for the levels of proviral integration by Alu-PCR. *: P b 0.05 and **: P b 0.01 over untreated cells,
respectively.
179S. Agostini et al. / EBioMedicine 21 (2017) 170–181spatialmodiﬁcation in theα1 structure, such as to abolish interaction of
Tat to the C-terminus. Consistent with this possibility, analysis of the
protein structure obtained in the presence of ouabain (Yatime et al.,
2011) indicates that the drug indeed induces a modiﬁcation of the sur-
face formed by the C-terminal cytosolic loops.
What is molecular function of extracellular Tat release? Past work
from several laboratories has indicated that extracellular Tat exerts a
number of pleiotropic activities when released outside the producing
cells, ranging from stimulation of gene expression to inhibition of the
immune response (reviewed in: (Fittipaldi and Giacca, 2005)). A non
mutually exclusive, but perhaps more intriguing possibility is that amajor function of extracellular Tat is to increase virion infectivity. In-
deed, our experiments show that HIV-1 viral preparations, either
pseudotyped or carrying a natural Env protein, are signiﬁcantly less in-
fectious when produced in the presence of ouabain; infectivity could be
rescued by the addition of recombinant Tat or supernatants containing
the protein. The results of these experiments indicate that amajor func-
tion of secreted Tat is to increase HIV-1 virion infectivity on its primary
CD4+ T cell targets. This effect is likely to be mediated by the associa-
tion of Tat, on the surface of virions, with cell surface-associated hepa-
ran sulfate proteoglycans (Rusnati et al., 1998; Tyagi et al., 2001); the
observation that infection of the CHO psg A-745 mutant, which lack
180 S. Agostini et al. / EBioMedicine 21 (2017) 170–181proteoglycan biosynthesis, byHIV-1 virions produced in the presence of
ouabain cannot be rescued by exogenous Tat addition is consistentwith
this possibility.
Of note, cell treatment with peptides corresponding to the three
short cytoplasmic sequences in the C-terminal domain of theα1 protein
both inhibited non canonical Tat secretion and suppressed HIV-1 infec-
tion.While no drugs are currently available in the clinics targeting Tat or
its transactivation functions in the nucleus, the efﬁcacy of these peptides
suggests that the competitive inhibition of the Tat-Na+,K+-ATPase α1
subunit interaction might represent a novel strategy for the develop-
ment of alternative anti-HIV-1 compounds. The design of derivatives
of these peptides, or of their peptidomimetics, or the identiﬁcation of
small chemical molecules able to interfere with Tat-α1 binding might
represent exciting avenues for future pharmacological development.
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